Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26167724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Victor I Seledtsov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Petrovsky National Research Centre of Surgery, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Monoclonal, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Overexpression of growth factor receptors and immunosuppressive molecules is a hallmark of many tumour cells, distinguishing them from normal tissue. This co-expression enables tumours both to exploit proliferative signalling and to evade immune surveillance. Here, we propose a strategy that employs a combination of monoclonal antibodies (mAbs) targeting two distinct antigens (Ags) at sub-cytotoxic doses. This approach aims to achieve a threshold cytotoxic density of immune complexes selectively on malignant cells expressing both target Ags, while sparing normal cells that express only one. Typically, the first target Ag may be a growth factor receptor, such as epidermal growth factor receptor (EGFR and HER1), epidermal growth factor receptor 2 (HER2), or vascular endothelial growth factor receptor 2 (VEGFR2), and the second, an immunoinhibitory molecule, such as programmed death-ligand 1 (PD-L1). Selective mAb-mediated tumour destruction is expected to enhance neoantigen (NeoAg) presentation to the immune system, while the blockade of PD-1/PD-L1 interactions should further stimulate anti-tumour immune responses. Notably, this strategy can be implemented using clinically approved therapeutic mAbs, potentially enabling rapid translation into clinical practice without extensive regulatory hurdles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Petrovsky National Research Centre of Surgery, 119991 Moscow, Russia.
- Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.
- National Cancer Institute, 08406 Vilnius, Lithuania.
ORCID-Profile: Victor I Seledtsov, Alexei von Delwig
Zitieren
APA
Seledtsov, V. I., Seledtsova, G. V., Darinskas, A., & von Delwig, A. (2025). Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167724
Vancouver
Seledtsov VI, Seledtsova GV, Darinskas A, von Delwig A. Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167724
BibTeX
@article{Seledtsov2025,
author = {Seledtsov, Victor I and Seledtsova, Galina V and Darinskas, Adas and von Delwig, Alexei},
title = {Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26167724}
}
EUVIMED